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Human dendritic cells (DC) can be differentiated from blood monocytes in the presence of GM-CSF and IL-4 and matured by
lipopolysaccharide (LPS). Vitamin D3 inhibits the maturation of human DC measured by changes in surface expression of HLA-
DR,CD14,CD40,CD80,CD83,andCD86.WehereexaminethefunctionofvitaminD3 during DC maturation. One of the earliest
changes to LPS-induced maturation was an increase in CD83 expression. Vitamin D3 inhibited the increase in expression of HLA-
DR, CD40, CD80, CD83, and CD86 and the decrease in expression of CD14, which was paralleled morphologically by vitamin
D3-induced inhibition of dendritic cell differentiation. Vitamin D3 acted in synergy with the TLR agonists LPS and peptidoglycan
(PGN) in inducing IL-6, IL-8, and IL-10, whereas vitamin D3 completely inhibited LPS-induced secretion of IL-12. The synergy
occurredatconcentrationswhereneithervitaminD3 northeTLRagonistsaloneinduced measurablecytokinesecretion. BothLPS
and PGN enhanced the level of the vitamin D3 receptor (VDR). Taken together, these data demonstrated that vitamin D3 and TLR
agonists acted in synergy to alter secretion of cytokines from human DC in a direction that may provide an anti-inflammatory
environment.
1. Introduction
Dendritic cells (DC) are highly specialized, professional
antigen-presenting cells (APC) that orchestrate the immune
response via integration of a variety of signals [1]. Immuno-
suppressiveandanti-inflammatorycompoundslikeIL-10[2],
1𝗼,25-dihydroxyvitaminD3 [3–5],andTGF-𝗽[6]ind uceDC
with tolerogenic properties in vitro.Th e s eD Ca r eg e n e r a l l y
c h a r a c t e r i z e db ya ni m m a t u r eo rs e m i m a t u r ep h e n o t y p e ,
with low expression of costimulatory molecules. In addition,
tolerogenic DC produce low amounts of proinflammatory
cytokines and high amounts of anti-inflammatory cytokines.
Interactions between DC and regulatory T cells (Treg)
facilitatetheimmunosuppression,immatureDCinduceT reg,
and vice versa Treg prepare DC to become immunosuppres-
sive [7, 8].
ThebiologicalactiveformofvitaminDismediatedbythe
active hormonal form 1𝗼,25-dihydroxyvitamin D3 (hereafter
referred to as vitamin D3). Its intracellular transcriptional
effects are mediated through binding to the vitamin D
receptor(VDR),whichsubsequentlyfunctionsasatranscrip-
tion factor. VDR is constitutively expressed in APC, such
as macrophages and DC, and is inducible in activated T
lymphocytes [9–11].
Several studies have demonstrated immunosuppressive
effects of vitamin D3 on the functions of DC. In vitro
maturation of both human and mouse DC in presence of
vitamin D3 lead to reduced expression of MHC-II and the
costimulatory molecules CD40, CD80, and CD86 resulting
in an enhanced production of IL-10 and a reduced secretion
of IL-12 [12, 13].
Vitamin D3 deficiency has been associated with a higher
rate of several diseases, including multiple sclerosis (MS)
[14, 15]. Moreover, administration of vitamin D3 in the
animal model experimental autoimmune encephalitis (EAE)
suppressed the development and progression of disease [16],
and vitamin D3 has also been shown to ameliorate several
other models of autoimmune diseases [17, 18].
Infection with Gram-negative bacteria provides lipo-
polysaccharide (LPS), which contains pathogen-associated
m o l e c u l a rp a t t e r n s( P A M P )t h a tf u n c t i o na saT o l l - l i k e
receptor (TLR) ligand. LPS is detected by TLR4 and is one
of the major components used for inducing maturation of
monocyte-derived DC in vitro [19]. TLR are expressed by2 Clinical and Developmental Immunology
many APC and activate an intracellular signaling pathway
that leads to transcriptional activation of proinflammatory
genes and innate effector molecules [20].
It is feasible that PAMP and TLR ligands interfere with
vitamin D3 functions in the immune system. This would be
consistent with the fact that individuals with severe vitamin
D3 deficiencieshaveanincreasesusceptibilitytointracellular
infections [21] .Ar e c e n ts t u d ys h o w st h a tt h ei n fl u e n c eo f
vitamin D3 on TLR4 ligand-induced activation of APC is
dependent on the order of VDR and TLR4 engagement [9].
To further study the interplay between TLR agonists and
vitaminD3,weexaminedthematurationandcytokineprofile
of DC differentiated in vitro from human peripheral blood
monocytes.
2. Materials and Methods
2.1.EthicalApproval. Thestudywasconductedinaccordance
with the Ethical Declaration of Helsinki. The project was
approved by the local Ethics Committee on Biomedical
Research Ethics (j. no20090210).
2.2. Isolation of Peripheral Blood Mononuclear Cells. Human
peripheral blood mononuclear cells (PBMC) were isolated
f r o mb u ff yc o a t s( B l o o db a n k ,A a r h u sU n i v e r s i t yH o s p i t a l ,
Skejby, Denmark) of healthy donors using Ficoll-Paque
PLUS (GE Healthcare BioScience AB, Uppsala, Sweden)
with density gradient centrifugation according to the man-
ufacturer’s procedure. PBMC were cryopreserved in 90%
heat-inactivated fetal bovine serum (FBS) (Sigma-Aldrich,
SaintLouis,USA)supplementedwith10%dimethylsulfoxide
(DMSO)(Sigma-Aldrich,SaintLouis,MO,USA)ataconcen-
tration of 10
7 cells/mL and stored at −80
∘Cu n t i lu s e .
2.3. Isolation of CD14
+ Monocytes by EasySep Negative Selec-
tion. F o rt h ei s o l a t i o no fm o n o c y t e s ,P B M Cw e r er a p i d l y
thawed and resuspended in phosphate-buffered saline (PBS)
supplemented with 2% FBS and 1mM EDTA. From these
cells, monocytes were purified by negative immunomagnetic
depletion using the EasySep Human Monocyte Enrichment
Kit according to manufacturer’s instructions (cat. no 19059,
Stemcell Technologies, Grenoble, France). In brief, cells were
resuspended at a concentration of 5 × 10
7 in PBS (without
Mg
2+ and Ca
2+)+2 %F B S+1m ME D T A .F i r s t ,c e l l sw e r e
labeledwithEasySepHumanMonocyteEnrichmentCocktail
for 10min at 4
∘C, and then the EasySep D Magnetic Particles
for Monocytes were incubated with the cell suspension for
5minat4
∘C.Finally,thesuspensionwasplacedintotheEasy-
Sep Magnet, and the desired negatively selected untouched
monocytes were collected. To increase purity, the magnetic
isolation procedure was repeated once, and the harvested
cells were kept cold. The purity of the untouched monocytes
was evaluated by flow cytometry for CD14 expression. Cells
were collected and labeled with FITC-conjugated mouse
anti-CD14 monoclonal antibody (T¨ UK4, DAKO Denmark
A/S,Glostrup,Denmark).Cellpopulationswereanalyzedon
a Cytomics FC500 flow cytometer (Beckman-Coulter) and
with FlowJo software (Tree Star, Ashland, USA). The purity
ranged from 85 to 95% (data not shown).
2.4. Generation of Monocyte-Derived Dendritic Cells. The
purified monocytes were washed twice and cultured in 6-
well plates (Techno Plastic Products) at a density of 0.5–
0.7 × 10
6 cells/mL in 1.2mL of RPMI 1640 medium (Gibco,
LifeTechnologies,UK)supplementedwith2%normalhuman
serum type AB (NHS AB), 2mM glutamine, and 20𝜇g/mL
gentamicin (Gibco). The cultures were established in the
presence of 100ng/mL recombinant human GM-CSF (Bayer
HealthcareAG,Leverkusen,GermanyorPeprotech,London,
UK) and 20ng/mL recombinant human IL-4 (Immunotools
GmbH, Friesoythe, Germany). The plates were incubated at
37
∘Cw i t h5 %C O 2 for six days. On day 3, the cultures were
supplemented with 360𝜇L fresh medium supplemented with
100ng/mL GM-CSF and 20ng/mL IL-4. On day 5, 1.56mL
fresh medium supplemented with 100ng/mL GM-CSF and
20ng/mL IL-4 was added to the cultures together with 0, 20,
or 100nM of 1𝗼,25-dihydroxyvitamin D3 (Sigma-Aldrich) as
indicated. On day 6, either mock (medium), bacterial LPS
(E. coli O111:B4, LPS ultrapure cat. no. tlrl-3pelps, InvivoGen,
San Diego, USA) in concentrations of 0, 0.01, 0.1, 1, 10,
or 100ng/mL, or PGN (from S. aureus,c a t .n o .t l r l - p g n s a ,
InvivoGen) in concentrations of 0, 0.1, 0.5, 1, 5, or 10𝜇g/mL
was added during the last 24hrs of culture. On day 7, all
supernatants were collected and frozen at −70
∘Ca n da l lc e l l s
were harvested for subsequent phenotypic and functional
analyses.
2.5. Morphological Examination. In order to examine the
morphologicalmaturationofthecells,viabilityandmorphol-
ogywereevaluatedbylightmicroscopy(LeicaMicrosystems)
ofthecellsinthe6-wellplatesatamagnificationof×10or×40
prior to harvest.
2.6. Flow Cytometric Analyses. Harvested cells were washed
t w i c ei nP B Sa n dr e s u s p e n d e di n1 0 0𝜇LP B Ss u p p l e m e n t e d
with 0.5% bovine albumin serum (BSA) and 0.1% sodium
azide for staining. Cells were incubated for 10min at
room temperature with an Fc receptor blocking solution
(BioLegend, San Diego, USA). Next, cells were incubated at
4
∘Cf o r3 0m i nw i t ht h ef o l l o w i n gm o n o c l o n a lm o u s e - a n t i -
human antibodies (mAb): anti-HLA-DR FITC (L243, BD
Biosciences), anti-CD14 FITC (T¨ UK4, DAKO), anti-CD40
PE(5C3,BDBiosciences),anti-CD80PE(MAB104,Beckman
Coulter), anti-CD83 PE-Cy5 (HB15e, BD Biosciences), and
anti-CD86 PE-Cy5 (2331 FUN-1, BD Biosciences). After
staining, cells were washed twice in PBS supplemented
with 0.5% BSA and 0.1% sodium azide and resuspended
in PBS with 0.99% paraformaldehyde. Flow cytometry was
performed on a Cytomics FC-500 flow cytometer (Beckman
Coulter), and all subsequent analyses were made in FlowJo
software (Tree Star).
2.7.QuantificationofCytokines. Forcytokineassessment,su-
pernatants from DC cultures were thawed and centrifuged
shortly and the content of IL-6, IL-8, IL-10, and IL-12p70Clinical and Developmental Immunology 3
was measured with enzyme-linked immunosorbent assay
(ELISA). Concentrations of IL-6, IL-8, IL-10, and IL-12p70
were measured using DuoSet ELISA kits (R&D Systems)
according to the manufacturer’s instructions. The spec-
trophotometer Versamax ELISA microplate reader (Molecu-
larDevices,LLC,Sunnyvale,USA)andSoftmaxProsoftware
(Molecular Devices) were used to measure and analyze the
samples.
2.8. Western Blotting Analysis/Cell Lysis and Immunoblotting.
Whole-cell extracts were prepared using 1x lysis buffer (Cell
Signaling Technology, Beverly, MA, USA) supplemented
with 1mM PMSF, 5mM NaF, and Complete Mini Protease
Inhibitor (Roche Diagnostics, Basel, Switzerland) at a con-
centration recommended by the manufacturer. Lysates were
centrifuged at 2.600×gf o r5 m i n ,f o l l o w e db y2 0 . 0 0 0 ×g
for 10 min, and whole-cell extracts were immediately frozen
at −70
∘C. Proteins were separated in XT Criterion 12%
gels (BioRad Laboratories Inc, Hercules, CA, USA) using
XT MOPS running buffer (Bio-Rad) for 1h and 30min at
175V and subsequently transferred to nitrocellulose mem-
branes for 1h and 45min at 300mA. Detection of VDR
was performed using anti-VDR mAb (sc-13133) (Santa Cruz
Biotechnology Inc, Dallas, TX, USA) diluted 1: 1000, and
GAPDH was detected using anti-GAPDH antibody (Santa
Cruz Biotechnology) diluted 1: 2000. The secondary anti-
bodies were horseradish peroxidase-conjugated rabbit anti-
mouse or swine anti-rabbit antibody (Dako) diluted 1: 2000.
All antibodies were diluted in 5% skimmed milk in TBS
with 0.1% Tween-20. Ponceau-S staining was performed as
a loading control. Immunoblots were developed using Super
Signal West Femto Maximum Sensitivity Substrate (Thermo
Scientific, Rockford, IL, USA).
3. Results
3.1. LPS Induces Rapid Maturation of DC, Which Is Inhibited
byVitaminD3. Asexpected,vitaminD3 added24hrspriorto
LPS treatment inhibited LPS-induced maturation measured
by the expression of surface molecules 24hrs after the addi-
tion of LPS (Figure 1(a)). Conversely, vitamin D3 prevented
thedownregulationofCD14expression,indicatingablockin
maturation of immature DC (Figure 1(a)). To further explore
the kinetics, cells were examined 4hrs after addition of LPS.
In the absence of vitamin D3, DC had already upregulated
CD83 and downregulated CD14 after 4hrs of LPS treatment,
whereas only minor or no changes were observed for HLA-
D R ,C D 8 0 ,C D 8 6 ,a n dC D 4 0 .Th u s ,u p r e g u l a t i o no fC D 8 3
appears to be an early event during DC maturation. The
presence of vitamin D3 partially inhibited upregulation of
CD83 almost to the same degree as observed after 24hrs.
The early induction of DC maturation was morpholog-
ically visible as dendritic formations as early as 4hrs after
the addition of LPS, but more pronounced after 24hrs. The
presence of vitamin D3 inhibited the outgrowth of these
processes (Figure 1(b)).
3.2. Vitamin D3 Is Necessary for LPS-Induced Secretion of
IL-6, IL-8, and IL-10. The presence of vitamin D3 inhibited
the maturation of differentiated DC. To examine whether
vitaminD3 influencedthecytokinesecretioninducedbyLPS,
differentiatedDCweretreatedwithvariousconcentrationsof
LPS and monitored for the secretion of IL-6, IL-8, and IL-10
in theabsence or presence of either 20 or 100nM vitaminD3.
These concentrations of vitamin D3 did not induce cytokine
secretionfromDC.AlthoughLPSinducedadose-dependent
secretion of IL-6, IL-8, and IL-10, the presence of vitamin D3
wasabletofurtherenhancethissecretion(Figures2(a)–2(c)).
Importantly,atlowdosesofLPS,cytokineswereonlyinduced
inthepresenceofvitaminD 3,despitethefactthatneitherLPS
alone nor vitamin D3 alone induced measurable cytokines.
These data demonstrated that vitamin D3 acted in synergy
with LPS to induce the secretion of IL-6, IL-8, and IL-10.
3.3. Vitamin D3 Inhibits LPS-Induced IL-12 Secretion. Since
vitamin D3 is thought to inhibit the proinflammatory
response, we next examined whether IL-12, a cytokine that
promotes a Th1-like response, was affected by vitamin D3.
ThepresenceofLPSatconcentrationsabove1ng/mLinduced
highlevelsofIL-12p70(Figure 2(d)).I nthepresenceofeither
20 or 100nM vitamin D3, the detection of LPS-induced
IL-12p70 was completely abolished. This demonstrated that
vitamin D3 is a potent inhibitor of IL-12.
3.4. Vitamin D3 Is Necessary for PGN-Induced Secretion of
IL-6, IL-8, and IL-10. To test whether LPS was the only
T L Rl i g a n da b l et oi n d u c ec y t o k i n e sa n da c ti ns y n e r g yw i t h
vitamin D3, differentiated DC were treated with the TLR2
agonist PGN. PGN was able to induce high levels of IL-8
and low levels of IL-6 and IL-10 at high concentrations of
PGN(Figures3(a)–3(c)).However ,inthepresenceofvitamin
D3, PGN-induced cytokine secretion from differentiated
DC was synergistically increased for IL-6, IL-8, and IL-
10 (Figures 3(a)–3(c)). In contrast to LPS, PGN did not
induce IL-12 (Figure 3(d)). This indicated that PGN, similar
to LPS, induced cytokine secretion from DC in synergy with
vitamin D3.
3.5. LPS and PGN Enhance Expression of the Vitamin D
Receptor. Vitamin D3 exerts its function after binding to an
intracellular receptor, VDR. To examine whether LPS could
increasethesensitivityofDCforvitaminD3,theproteinlevel
of VDR was measured by western blotting. In the absence of
vitaminD3 orTLRagonists,alowlevelofVDRwasdetectable
(Figure 4). However, the presence of LPS or PGN increased
the level of VDR, which was not further affected by the
presence of vitamin D3 (Figure 4). This indicated that LPS or
PGNwasabletoenhancethesensitivityofDCforvitaminD3
by increasing the expression of its receptor.
4. Discussion
ThegenerationofTregisinpartcontrolledbythematuration
of DC. In mice, treatment with vitamin D3 induces a
regulatory T-cell profile with increased expression of IL-10,
TGF-𝗽,F o x P 3 ,a n dC T L A - 4a n das i g n i fi c a n tr e d u c t i o no f
IL-12p70, IL-23p19, IL-6, and IL-17 [22]. We also observed4 Clinical and Developmental Immunology
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Figure1:VitaminD3 inhibitsLPS-inducedDCmaturation.(a)DCweredifferentiatedinthepresenceorabsenceofvitaminD3 and matured
with LPS for 4hrs (upper panel) or 24hrs (lower panel) prior to flow cytometric analysis. DC were treated without vitamin D3 (vit D) and
LPS (red curve), without vitamin D3 and with LPS (blue curve), with vitamin D3 and without LPS (green curve), and with both vitamin D3
and LPS (yellow curve) and were stained with fluorescence-conjugated antibodies HLA-DR(FITC), CD80(PE), CD83(PC5), CD14(FITC),
CD40(PE), and CD86(PC5). Histograms represent collection of 5,000 events. (b) Morphology of the DC was examined by light microscopy
at ×10 magnification at 4 and 24hrs after mock or LPS treatment. Experiments are representatives of at least two independent experiments.
that vitamin D3 promoted a regulatory profile, promoting
IL-10 and inhibiting IL-12p70. Surprisingly, we found that
in synergy with LPS or PGN, vitamin D3 increased IL-6 in
cultures of differentiated DC. Whether the detection of IL-6
indicates a pro- or an anti-inflammatory profile is, however,
not clear. IL-6 may be associated with a soluble form of the
IL-6 receptor and this complex may mediate proinflamma-
tory reactions through a process known as transsignaling
[23]. Blockade of IL-6 transsignaling completely protected
gp130
F/F knock-in mutant mice from LPS hypersensitivity,
suggesting cross-talk between JAK/STAT and TLR pathways
[24]. On the other hand, the classical binding of IL-6 to
gp130/IL-6 receptor complexes on the cell surface may pro-
mote anti-inflammatory/regenerative reactions [23]. Thus,
further investigations may elucidate which one of these
scenarios is supported by vitamin D3.
I m p o r t a n t l y ,w ef o u n dt h a t ,a tv e r yl o wl e v e l so fL P S ,
vitamin D3 promoted the secretion of IL-8 in synergy with
LPS. That is, neither the concentration of 0.01ng/mL of LPS
nor the presence of vitamin D3 alone was able to induce this
cytokine. However, when added together, vitamin D3 and
LPS acted in synergy and induced in the order of 2–4ng of
IL-8. IL-8 is a major chemoattractant for the recruitment of
polymorphonuclear leukocytes that serve as part of the firstClinical and Developmental Immunology 5
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Figure 2: Vitamin D3 is necessary for LPS-induced secretion of IL-6, IL-8, and IL-10. DC were stimulated with 0, 20, or 100nM of vitamin
D3 (vitamin D) and 10-fold dilutions of LPS (from 100 to 0.01ng/mL). Cell-culture supernatants were assessed for IL-6 (a), IL-8 (b), IL-10 (c),
and IL-12 (d) by ELISA. Experiment is representative of at least two independent experiments.
line of defense against intruding bacteria. This emphasizes
thatbesidesitseffectontheadaptiveimmunesystem,vitamin
D3 also has important functions for the innate immune
response.
IL-8 has previously been shown to be induced by the
transformedcelllineTHP -1inthepresenceofvitaminD 3 and
agonistsofTLR2,TLR3,TLR4,NOD1,andNOD2[25].How-
ever,otherstudieshavereportedthatvitaminD3 inhibitedIL-
8p r od uctio ninr es po n set oIL -1𝗼inhumanperipheralblood
mononuclear cells, keratinocytes, and fibroblasts [26, 27],
although TLR and IL-1R are both signals through MyD88.
Inhibition of IL-8 by vitamin D3 has also been observed in
primary cultures of human periodontal ligament cells stimu-
lated with P. gingivalis, a Gram-negative bacteria containing
LPS [28]. Thus, the cell type, the presence of other cytokines,
and potentially virulence factors from microorganisms may
all be important for modulating the control exerted by
vitamin D3 on IL-8 secretion.
Although LPS is frequently used to mature monocyte-
derived human DC, other TLR agonist may serve the same
functions. LPS is a component of the outer membrane of
theGram-negativebacterialcellwall,whereasGram-positive
bacteria are characterized by a cell wall containing PGN, a
ligandforTLR2.Inagreementwiththeobservedfunctionsof
LPS,PGNalsoactedinsynergywithvitaminD3 forthesecre-
tionofIL-6,IL-8,andIL-10butwasunabletoinduceIL-12p70
as did LPS. This indicates that PGN from Gram-positive bac-
teriamayalsohavetheabilitytoprimetheresponsetowardsa
regulatoryT-cell profileand that PGN also induces chemoat-
tractants for recruiting polymorphonuclear leukocytes.6 Clinical and Developmental Immunology
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Figure3:VitaminD3 isnecessaryforPGN-inducedsecretionofIL-6,IL-8,andIL-10.DCwerestimulatedwith0,20or100nMofvitaminD3
and dilutions of PGN (from 0.1 to 10𝜇g/ml). Cell-culture supernatants were assessed for IL-6 (a), IL-8 (b), IL-10 (c), and IL-12 (d) by ELISA.
Experiment is representative of at least two independent experiments.
The level of VDR in part determines the sensitivity of
DC for vitamin D3.L i ue ta l .f o u n dt h a tt h eM. tuberculosis-
derived lipopeptide, which is a TLR2/1 ligand, induced the
expression of VDR. In addition, they observed that vitamin
D3 upregulated the antimicrobial peptide cathelicidin, which
is important for the killing of intracellular bacteria [19].
However, since most bacteria are extracellular, we examined
the general Gram-negative and Gram-positive TLR ligands:
LPS (TLR4) and PGN (TLR2). We found that these TLR
l i g a n d sw e r ea l s oa b l et oi n c r e a s et h el e v e lo fV D R .Th e
shifting by vitamin D3 of the immune response towards a
regulatory profile as opposed to a proinflammatory response
may be of benefit for the invading microorganisms. In this
view, the upregulation of VDR by both LPS and PGN may
further enhance the effect of vitamin D3 and thus further
prevent the antimicrobial defense. The inhibition of IL-8
induction by P. gingivalis [28], as mentioned previously,
further indicates that the microorganism may have evolved
mechanisms to avoid part of these host innate responses.
Whether this is a general feature remains to be investigated.
Conversely,wespeculate thattheseeffectsofvitaminD3 may
also prevent unnecessary inflammatory reactions towards
commensal microorganisms present in the gut. The shifting
towards a regulatory profile by vitamin D3 may also be
of benefit during graft-versus-host disease (GVHD) [29].
However, whether the anti-inflammatory actions of vitamin
D3 can be enhanced in an in vivo setting by the addition of
low levels of TLR agonists remains to be examined.Clinical and Developmental Immunology 7
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Figure 4: LPS and PGN act in synergy with vitamin D3 to enhance
expression of the vitamin D receptor. (a) The levels of VDR protein
in DC were measured by the western blotting of whole-cell lysates
from DC cultures stimulated with either mock, 10ng/mL LPS, or
10𝜇g/mL PGN in the absence or presence of 100nM vitamin D3.
GAPDH was used as a loading control. (b) The band intensity in (a)
was quantified and normalized to GAPDH as a VDR/GAPDH ratio
(VDR expression).
5. Conclusions
In conclusion, human DC maturation is inhibited by vitamin
D3. LPS and PGN (TLR4 and TLR2 agonists) increase the
levelofVDRandactinsynergywithvitaminD 3 forinduction
of IL-6, IL-8, and IL-10, whereas LPS induction of IL-12 is
inhibitedbyvitaminD3.PGNdoesnotinducemeasurableIL-
1 2 .Th u s ,v i t a m i nD 3 synergizes with TLR agonists in modu-
latinghumanDCcytokinesecretionduringmaturation.This
may generate an anti-inflammatory environment that favors
the induction of regulatory cells.
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